AstraZeneca Pauses £200M Expansion in UK Amid Pharma Uncertainty
AstraZeneca has paused a £200 million ($271 million) expansion of its Cambridge research site.
The move follows AstraZeneca's abandonment of a £450 million vaccine plant in northwest England earlier this year.
Merck also recently dropped plans for a $1.4 billion research centre in London, citing a 'challenging business environment'.
AstraZeneca plans to invest $50 billion in the US by 2030, indicating a shift in investment priorities.